No Data
No Data
Buy Rating for Mereo Biopharma Group Plc Driven by Promising Phase 3 Study of Setrusumab in Osteogenesis Imperfecta
Mereo BioPharma Group Plc (MREO): A Bull Case Theory
Cantor Fitzgerald Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $7
Mereo Wins New Overweight at J.P. Morgan Ahead of Trial Readouts
European Equities Traded in the US as American Depositary Receipts Edge Higher in Thursday Trading
This Roper Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday